Project description DEENESFRITPL New device prevents risk of re-herniation Lumbar disc herniation causes extreme back and leg pain and leads to disability. The standard care is a surgical intervention (discectomy). However, discectomy doesn’t prevent the risk of re-herniation through the same disc defect, requiring an expensive and complicated re-operation. NEOS Surgery has developed the DISC care™ Hernia Blocking System, which prevents re-herniation, confronts the clinical problem and reduces healthcare costs. The EU-funded DISC care project will perform the clinical trial, complete product range and achieve CE marking under the new EU Medical Device Regulation to prepare the market launch of the product in 2023. DISC care™ will enter a Blue Ocean market segment and become the first European hernia blocking device. Show the project objective Hide the project objective Objective Lumbar disc herniation occurs when the intervertebral disc breaks and its nucleus bursts out pressing the nerves. It causes extreme back and leg pain, numbness and disability. To relieve the pain, a surgical intervention (discectomy) is the standard of care, consisting of removing the herniated material. Disc herniation is the most frequent cause of spine surgery for working-age patients and in 2019 more than 1M lumbar discectomies were performed WW. Although discectomy may work in some cases, a high portion of patients have a high risk of re-herniation through the same disc defect, requiring a costly and complex re-operation. To avoid re-herniation, some surgeons remove a larger amount of nucleus, making it unlikely to re-herniate, but compromising the disc functionality and causing chronic back pain. NEOS Surgery has developed the DISC care™ Hernia Blocking System, an implantable strong barrier that prevents re-herniation while allowing surgeons to remove the minimum disc tissue. DISC care™ will solve an unmet clinical need while reducing healthcare costs. The internationally patented DISC care™, has completed several years of development and pre-clinical testing with excellent results. The product is now ready to overcome the final barriers for its market launch in 2023: clinical trial, complete product range and CE-marking under the new EU MDR. The DISC care™ will enter a “Blue Ocean” market segment, being the first Hernia Blocking device from a European company and the second worldwide. The DISC care™ will radically impact NEOS turnover, with an exponential growth 2027. Moreover, it will accelerate NEOS growth, creating a very profitable financial structure for future expansion. NEOS multidisciplinary team will be key for the DISC care™ success: we have the experience to transform an idea into a global commercial medical device, thanks to our current line of cranial closure devices. Fields of science medical and health sciencesclinical medicinesurgerysurgical proceduresmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance Keywords DISC care Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2 - SME instrument phase 2 Coordinator NEOS SURGERY SL Net EU contribution € 1 934 572,50 Address PASEO MIKELETEGI 2 PARQUE TECNOLOGI 20009 DONOSTIA SAN SEBASTIAN Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Noreste País Vasco Gipuzkoa Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 763 675,00